TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35301888

Group type: EXPERIMENTAL
Intervention: rosuvastatin monotherapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: rosuvastatin/ezetimibe combination therapy
Number of subjects: 63
Study: 34268884

Group type: EXPERIMENTAL
Intervention: Oral metformin (1 g) with codeine (25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous metformin (0.5 g) with codeine (25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral metformin (1 g) without codeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous metformin (0.5 g) without codeine
Number of subjects: 0
Study: 32964756

Group type: EXPERIMENTAL
Intervention: Negative pressure dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (fixation strips)
Number of subjects: 0
Study: 34743319

Group type: COMPARATOR
Intervention: Escitalopram (10 mg daily for 7 days, then 20 mg daily for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo (14 days before psilocybin administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psilocybin (25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Escitalopram and Psilocybin
Number of subjects: 0
Study: 35777867

Group type: EXPERIMENTAL
Intervention: Physical activity (1 month) followed by cognitive training (1 month)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cognitive training (1 month) followed by physical activity (1 month)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Active breathing condition (psychoeducation and resonance frequency breathing for 1 month) followed by combined physical activity and cognitive training (1 month)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Wash-out periods (15 days) between interventions
Number of subjects: 81
Study: 32026495

Group type: EXPERIMENTAL
Intervention: NEMU method
Number of subjects: 162

Group type: COMPARATOR
Intervention: Weight-based equation
Number of subjects: 162
Study: 34423676

Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (with a 7-day lead-in at 90 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alectinib 600 mg twice daily
Number of subjects: 0
Study: 32660347

Group type: EXPERIMENTAL
Intervention: 2-mA stimulation
Number of subjects: 23
Study: 34718628

Group type: EXPERIMENTAL
Intervention: Metreleptin (≥ 0.15 mg/kg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no metreleptin)
Number of subjects: 10
Study: 32978119

Group type: COMPARATOR
Intervention: Dry standard retinoscopy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mirza tele-lens retinoscopy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cycloplegic standard retinoscopy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cycloplegic Mirza tele-lens retinoscopy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Dry retinoscopy methods
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cyclo retinoscopy methods
Number of subjects: 39
Study: 32039739

Group type: EXPERIMENTAL
Intervention: Emotion regulation training in addition to care as usual (multidisciplinary obesity treatment)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Care as usual (multidisciplinary obesity treatment)
Number of subjects: 140
Study: 34138499

Group type: EXPERIMENTAL
Intervention: Collagen membrane (Bio‐Gide) used in regenerative endodontics
Number of subjects: 80

Group type: COMPARATOR
Intervention: No collagen membrane used in regenerative endodontics
Number of subjects: 80
Study: 34283037

Group type: EXPERIMENTAL
Intervention: MT‐Phoenix (gamified smartphone-based intervention)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 77
Study: 32583907

Group type: EXPERIMENTAL
Intervention: Minesapride 10 mg/d
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Minesapride 20 mg/d
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Minesapride 40 mg/d
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study: 36142073

Group type: EXPERIMENTAL
Intervention: Circling Curriculum for Metacognition Training (CCMT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Routine teaching activities (Control)
Number of subjects: 47
Study: 34455152

Group type: EXPERIMENTAL
Intervention: Bilateral continuous T8 ESP blocks with a programmed intermittent bolus regimen of 10 mL 0.2% ropivacaine every 3 h for 48 h (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intrathecal morphine (ITM) 400 μg (n=30)
Number of subjects: 60
Study: 35709415

Group type: COMPARATOR
Intervention: FLOT alone (arm A)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: FLOT with trastuzumab and pertuzumab (arm B)
Number of subjects: 81
Study: 32037195

Group type: EXPERIMENTAL
Intervention: Demcizumab (DLL4 targeted IgG2 humanized monoclonal antibody) combined with paclitaxel (2.5 mg/kg and 5 mg/kg doses); administered on days 1 and 15 for 3 cycles, followed by paclitaxel until unacceptable toxicity or disease progression.
Number of subjects: 19
Study: 35319005

Group type: EXPERIMENTAL
Intervention: Rice-based sports beverage (RB)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sucrose-based sports beverage (SB)
Number of subjects: 18
Study: 34819150

Group type: EXPERIMENTAL
Intervention: Unilateral quadratus lumborum block (QLB) with 0.375% bupivacaine 0.5 mL/kg (QLB group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional scheme (control group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Unilateral quadratus lumborum block (QLB)
Number of subjects: 56
Study: 32191267

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab (protocol-guided treatment)
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Worse visual acuity (20/200-20/320)
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Larger neovascularization area (>4 disc areas)
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Switched drug regimen
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Single-nucleotide variants ARMS2 (TT variant)
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Single-nucleotide variants HTRA1 (AG variant)
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Single-nucleotide variants HTRA1 (AA variant)
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Sub-retinal pigment epithelium thickness (>275 μm)
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Worse fellow-eye visual acuity (<20/40)
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Fellow-eye GA
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Pseudodrusen in either eye
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Subretinal fluid
Number of subjects: 1107
Study: 33943011

Group type: EXPERIMENTAL
Intervention: S + POCT (surgery plus postoperative chemotherapy)
Number of subjects: 782

Group type: COMPARATOR
Intervention: S (surgery alone)
Number of subjects: 782
Study: 32919288

Group type: EXPERIMENTAL
Intervention: Free-water imaging in early course schizophrenia
Number of subjects: 79
Study: 35459106

Group type: EXPERIMENTAL
Intervention: Guided imagery intervention (listened to audio file for 25 min at home)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 33744963

Group type: EXPERIMENTAL
Intervention: Daily co-trimoxazole
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Weekly chloroquine
Number of subjects: 1499

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 1499
Study: 35779599

Group type: EXPERIMENTAL
Intervention: Leaflet resection strategy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Leaflet preservation strategy
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Patients with elevated gradients
Number of subjects: 104
Study: 33901547

Group type: EXPERIMENTAL
Intervention: Piezoelectric device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (surgical carbide burs and curettes)
Number of subjects: 40
Study: 32466923

Group type: EXPERIMENTAL
Intervention: High hedonic rating of porcini mushrooms due to aroma notes (seasoning-like, roasted, cacao-like, smoky)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low hedonic liking of porcini mushrooms due to raw mushroom-like, cardboard-like, sweaty attributes
Number of subjects: 0
Study: 35278693

Group type: EXPERIMENTAL
Intervention: Customized Adherence Enhancement for Adolescents and Young Adults (CAE‐AYA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 40
Study: 32170754

Group type: EXPERIMENTAL
Intervention: ABCNet
Number of subjects: 38

Group type: COMPARATOR
Intervention: DeepMedic, 3D U-Net, V-Net, Dense V-Net
Number of subjects: 38
Study: 34181360

Group type: EXPERIMENTAL
Intervention: 200 mg VLX-ER
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: 400 mg VLX-ER
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 32396775

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study: 33045861

Group type: EXPERIMENTAL
Intervention: Patient Information Sheets (PIS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Consent Forms (CF)
Number of subjects: 50
Study: 32959616

Group type: EXPERIMENTAL
Intervention: Regular or yearly influenza vaccination uptake among students (10.2%), patients (19.1%), and HCWs (35.6%).
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Having children as a predictor of vaccination uptake (adjusted OR = 3.8; 95% CI 1.2‐12.5).
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Self-reported level of knowledge as a predictor of vaccination uptake (OR = 16.3; 95% CI 1.4‐194.2).
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Fear of consequences of influenza as a barrier (OR = 0.2; 95% CI 0.1‐0.6).
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Barriers to vaccination include lack of information (31%), fear of adverse effects (29%), and perception of not being at risk (23%).
Number of subjects: 247
Study: 34261196

Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) training in the workplace
Number of subjects: 608
Study: 34249487

Group type: EXPERIMENTAL
Intervention: PIT tags
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (untagged)
Number of subjects: 200
Study: 33759038

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (HCT) in refractory MS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (HCT) in advanced SSc
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hematopoietic stem cell transplantation (HCT) in lupus
Number of subjects: 0
Study: 34255238

Group type: EXPERIMENTAL
Intervention: Cervitec F (chlorhexidine-fluoride varnish)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 23

Group type: COMPARATOR
Intervention: Duraphate varnish
Number of subjects: 23
Study: 33549193

Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg every 4 weeks
Number of subjects: 567

Group type: COMPARATOR
Intervention: Ustekinumab 45 mg or 90 mg every 12 weeks
Number of subjects: 567

Group type: COMPARATOR
Intervention: Placebo every 4 weeks
Number of subjects: 567
Study: 32535407

Group type: EXPERIMENTAL
Intervention: Social exclusion condition (experimental manipulation)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Social inclusion condition (control)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Feelings of rejection (post hoc mediation model)
Number of subjects: 117
Study: 35796152

Group type: EXPERIMENTAL
Intervention: Outpatient management (discharged within 24 hours)
Number of subjects: 776

Group type: COMPARATOR
Intervention: Inpatient management (discharged after 24 hours)
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Outpatient management
Number of subjects: 776

Group type: COMPARATOR
Intervention: Inpatient management
Number of subjects: 776
Study: 33636381

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both groups (ESWT and Surgery)
Number of subjects: 29
Study: 32252789

Group type: EXPERIMENTAL
Intervention: PRENACEL program (SMS intervention)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Standard prenatal care (Control)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Intervention group (not opting for PRENACEL)
Number of subjects: 186
Study: 33295965

Group type: EXPERIMENTAL
Intervention: Global Registries of Acute Coronary Events (GRACE) risk score (GRS) implementation
Number of subjects: 2318

Group type: EXPERIMENTAL
Intervention: Global Registries of Acute Coronies Events (GRACE) risk score (GRS) implementation
Number of subjects: 2318
Study: 32126972

Group type: EXPERIMENTAL
Intervention: Physical function tests (Six-Minute-Walk-Test, Sit-to-Stand-Test, grip strength, knee extension strength)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison to normative data
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison to other cancer populations
Number of subjects: 100
Study: 34157675

Group type: EXPERIMENTAL
Intervention: Exercise snacking
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Tai chi snacking
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combination of exercise snacking and tai chi snacking
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (UK National Health Service Web pages)
Number of subjects: 63
Study: 33755695

Group type: EXPERIMENTAL
Intervention: PTSD diagnosis
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Depression diagnosis
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Head trauma
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Physical violence exposure
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Suicide risk
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Memory loss
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Association of PTSD and depression with memory loss
Number of subjects: 200
Study: 32700217

Group type: EXPERIMENTAL
Intervention: TIME program (Telehealth-supported, Integrated care with CHWs, and MEdication-access)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Usual care (wait-list control)
Number of subjects: 89
Study: 34187117

Group type: EXPERIMENTAL
Intervention: EGCG (2 tablets, 300 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wheat flour (placebo)
Number of subjects: 50
Study: 36412344

Group type: EXPERIMENTAL
Intervention: CAF (Coronally Advanced Flap)
Number of subjects: 15

Group type: COMPARATOR
Intervention: CAF + Resorbable GTR membrane
Number of subjects: 15
Study: 33798978

Group type: EXPERIMENTAL
Intervention: Genetically predicted 1-SD increase in subjective wellbeing
Number of subjects: 455258

Group type: EXPERIMENTAL
Intervention: Genetically predicted greater neuroticism
Number of subjects: 455258

Group type: COMPARATOR
Intervention: Personality traits (agreeableness)
Number of subjects: 455258

Group type: COMPARATOR
Intervention: Personality traits (conscientiousness)
Number of subjects: 455258

Group type: COMPARATOR
Intervention: Personality traits (openness)
Number of subjects: 455258

Group type: COMPARATOR
Intervention: Personality traits (neuroticism)
Number of subjects: 455258

Group type: COMPARATOR
Intervention: Personality traits (extraversion)
Number of subjects: 455258
Study: 34927342

Group type: EXPERIMENTAL
Intervention: Subcision combined with cross-linked hyaluronic acid (HA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subcision combined with poly-l-lactic acid (PLLA) threads
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subcision alone
Number of subjects: 40
Study: 32331060

Group type: EXPERIMENTAL
Intervention: LEM5 (5mg)
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: LEM10 (10mg)
Number of subjects: 949

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 949
Study: 35579171

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Traditional Jiangnan diet high in plants (TJD)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control diet low in plants (CD)
Number of subjects: 253
Study: 34016536

Group type: EXPERIMENTAL
Intervention: Wearable Activity Technology and Action Planning (WATAAP) intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 35514231

Group type: EXPERIMENTAL
Intervention: 0.001% Edelweiss extract (EWDE)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Edelweiss extract formulation
Number of subjects: 3
Study: 33356027

Group type: EXPERIMENTAL
Intervention: Greater occipital nerve (GON) block
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Greater occipital nerve + supraorbital nerve (GON + SON) block
Number of subjects: 82
Study: 32821805

Group type: EXPERIMENTAL
Intervention: Resident-authored ECG email curriculum (10 multiple-choice ECG cases emailed biweekly over 6 months)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard training (control group)
Number of subjects: 129
Study: 35232647

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 152

Group type: COMPARATOR
Intervention: UDCA
Number of subjects: 152

Group type: COMPARATOR
Intervention: Digestive enzyme
Number of subjects: 152
Study: 33375442

Group type: EXPERIMENTAL
Intervention: Emotional eating
Number of subjects: 24968

Group type: EXPERIMENTAL
Intervention: Worries related to personal economy
Number of subjects: 24968

Group type: EXPERIMENTAL
Intervention: Worries related to health
Number of subjects: 24968

Group type: EXPERIMENTAL
Intervention: Psychological distress
Number of subjects: 24968

Group type: EXPERIMENTAL
Intervention: Intake of high-sugar foods and beverages
Number of subjects: 24968
Study: 33478428

Group type: EXPERIMENTAL
Intervention: Weekly rifapentine and isoniazid regimen (self-administered for 12 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Daily rifampicin and isoniazid regimen (self-administered for 12 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both arms (weekly rifapentine/isoniazid and daily rifampicin/isoniazid)
Number of subjects: 52
Study: 32019563

Group type: EXPERIMENTAL
Intervention: Employed mothers with short duration of maternity leave
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Full time employees
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Employees in private organizations
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Mothers without flexible work time
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Mothers not pumping breast milk
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Mothers without a lactation break
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Mothers with workplace far from their child
Number of subjects: 313
Study: 34697780

Group type: EXPERIMENTAL
Intervention: ApBM+ (n=26)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard-ApBM (n=19)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sham-ApBM (n=22)
Number of subjects: 67
Study: 33969866

Group type: EXPERIMENTAL
Intervention: Peer-delivered CBT-based intervention
Number of subjects: 177

Group type: COMPARATOR
Intervention: Attention control (general health advice)
Number of subjects: 177
Study: 35580239

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33041092

Group type: EXPERIMENTAL
Intervention: Prehabilitation (multimodal at home and in-hospital for approximately four weeks)
Number of subjects: 47
Study: 33552685

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (P)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Combination of pembrolizumab with platinum-based chemotherapy (PCT)
Number of subjects: 256
Study: 33093237

Group type: EXPERIMENTAL
Intervention: Exposure to TCE after age 50 years
Number of subjects: 38375

Group type: EXPERIMENTAL
Intervention: Exposure to TCE with over 20 years of latency
Number of subjects: 38375

Group type: EXPERIMENTAL
Intervention: Exposure to TCE associated with ER+ tumours after age 50 years
Number of subjects: 38375
Study: 35899371

Group type: EXPERIMENTAL
Intervention: Multimodal music program
Number of subjects: 84

Group type: COMPARATOR
Intervention: Active control Lego program
Number of subjects: 84

Group type: COMPARATOR
Intervention: No treatment control condition
Number of subjects: 84
Study: 34102783

Group type: EXPERIMENTAL
Intervention: Intranasal glucocorticoid (dexamethasone) after nasal endoscopic surgery
Number of subjects: 122

Group type: COMPARATOR
Intervention: Oral glucocorticoid (prednisone) one week before and three weeks after operation
Number of subjects: 122
Study: 35328996

Group type: EXPERIMENTAL
Intervention: Integrated Care Model (ICM) intervention
Number of subjects: 143

Group type: COMPARATOR
Intervention: Usual geriatric care (Control)
Number of subjects: 143
Study: 32277364

Group type: EXPERIMENTAL
Intervention: Single oral dose of bentysrepinine (50-900 mg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Multiple doses of bentysrepinine (300 mg and 600 mg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Single dose of bentysrepinine (600 mg) in food-effect study
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 94
Study: 34663696

Group type: COMPARATOR
Intervention: Placebo (no tenofovir disoproxil and emtricitabin (TDF/FTC))
Number of subjects: 203
Study: 34868486

Group type: EXPERIMENTAL
Intervention: Dog-training programme (n = 30)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Dogs' behaviour (measured in both groups)
Number of subjects: 53
Study: 36038416

Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 275

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 275
Study: 33872308

Group type: EXPERIMENTAL
Intervention: MRLocus method for Bayesian estimation of gene-to-trait effect from eQTL and GWAS summary data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRLocus method applied to five candidate causal genes
Number of subjects: 0
Study: 33691268

Group type: EXPERIMENTAL
Intervention: Bra prescription (wearing a prescribed bra every day for eight weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 18
Study: 32174470

Group type: EXPERIMENTAL
Intervention: 10 Hz high-frequency rTMS
Number of subjects: 385

Group type: COMPARATOR
Intervention: intermittent theta-burst stimulation (iTBS)
Number of subjects: 385
Study: 35148517

Group type: EXPERIMENTAL
Intervention: C1-ring osteosynthesis
Number of subjects: 73

Group type: COMPARATOR
Intervention: C1-2 fixation fusion
Number of subjects: 73